Oruka Therapeutics’ (ORKA) “Buy” Rating Reiterated at BTIG Research

Posted by Stanley Muller on Oct 22nd, 2026

BTIG Research restated their buy rating on shares of Oruka Therapeutics (NASDAQ:ORKA – Free Report) in a research note released on Monday morning,Benzinga reports. The firm currently has a $151.00 price objective on the stock.

Several other equities analysts have also commented on ORKA. Mizuho set a $120.00 price objective on shares of Oruka Therapeutics in a report on Thursday, September 3rd. Guggenheim reiterated a “buy” rating and issued a $200.00 target price on shares of Oruka Therapeutics in a report on Tuesday, August 11th. Wedbush set a $120.00 target price on Oruka Therapeutics in a research report on Thursday, September 24th. Weiss Ratings restated a “sell (d-)” rating on shares of Oruka Therapeutics in a research note on Tuesday, October 13th. Finally, HC Wainwright restated a “buy” rating and set a $120.00 price target on shares of Oruka Therapeutics in a research note on Thursday, September 24th. Ten research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $128.91.

Get Our Latest Research Report on ORKA

Oruka Therapeutics Stock Performance

Shares of ORKA opened at $79.92 on Monday. Oruka Therapeutics has a 12-month low of $25.11 and a 12-month high of $115.51. The company’s 50-day moving average price is $90.77 and its 200 day moving average price is $80.84.

Oruka Therapeutics (NASDAQ:ORKA – Get Free Report) last announced its earnings results on Monday, August 10th. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.04). On average, analysts forecast that Oruka Therapeutics will post -2.42 earnings per share for the current fiscal year.

Insider Activity at Oruka Therapeutics

In related news, SVP Arjun Agarwal sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, August 13th. The shares were sold at an average price of $106.66, for a total transaction of $1,066,600.00. Following the sale, the senior vice president directly owned 15,312 shares of the company’s stock, valued at $1,633,177.92. This represents a 39.51% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Joana Goncalves sold 7,947 shares of the stock in a transaction that occurred on Tuesday, September 15th. The stock was sold at an average price of $92.38, for a total transaction of $734,143.86. Following the sale, the insider owned 31,771 shares in the company, valued at approximately $2,935,004.98. This trade represents a 20.01% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Over the last quarter, insiders sold 154,950 shares of company stock worth $14,102,680. Corporate insiders own 23.49% of the company’s stock.

Institutional Trading of Oruka Therapeutics

A number of large investors have recently modified their holdings of ORKA. Nykredit A S purchased a new position in Oruka Therapeutics in the second quarter valued at $29,000. GAMMA Investing LLC increased its holdings in Oruka Therapeutics by 201.6% during the 3rd quarter. GAMMA Investing LLC now owns 374 shares of the company’s stock worth $31,000 after purchasing an additional 250 shares during the period. Caitong International Asset Management Co. Ltd purchased a new stake in Oruka Therapeutics during the 4th quarter worth about $67,000. Orion Capital Management LLC acquired a new stake in Oruka Therapeutics in the 2nd quarter valued at about $91,000. Finally, Royal Bank of Canada raised its position in Oruka Therapeutics by 178.5% in the 1st quarter. Royal Bank of Canada now owns 3,172 shares of the company’s stock valued at $155,000 after purchasing an additional 2,033 shares in the last quarter. Hedge funds and other institutional investors own 56.44% of the company’s stock.

Oruka Therapeutics Company Profile

(Get Free Report)

Oruka Therapeutics, Inc (NASDAQ: ORKA) is a clinical-stage biopharmaceutical company developing long-acting antibody therapies for immune-mediated diseases. The company is focused on creating treatments that may provide durable disease control while reducing the frequency of administration compared with conventional biologic therapies.

Oruka’s pipeline is centered on engineered monoclonal antibodies that target the interleukin-17 (IL-17) pathway, an important driver of inflammation in conditions such as psoriasis and other autoimmune diseases.